Completed PHASE2 INTERVENTIONAL 1-arm NCT03950830

Disulfiram and Cisplatin in Refractory TGCTs. (DISGCT)

Phase II Study of Disulfiram and Cisplatin in Refractory TGCTs.

Sponsor: National Cancer Institute, Slovakia

Interventions Disulfiram

Updated 7 times since 2019 Last updated: Oct 3, 2023 Started: May 14, 2019 Primary completion: Sep 30, 2021 Completion: Jan 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Germ Cell Tumor, this trial is completed. The trial is conducted by National Cancer Institute, Slovakia and has accumulated 7 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Nov 2023 — Jul 2024 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Feb 2023 — Nov 2023 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Feb 2023 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Sep 2020 — Jan 2021 [monthly]

Recruiting PHASE2
Jun 2019 — Sep 2020 [monthly]

Recruiting PHASE2

First recorded

May 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute, Slovakia

Data source: National Cancer Institute, Slovakia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bratislava, Slovakia